openPR Logo
Press release

Interstitial Lung Disease Clinical Trials Analysis 2024: FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

06-14-2024 07:28 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Interstitial Lung Disease Clinical Trials

Interstitial Lung Disease Clinical Trials

(Albany, United States) As per DelveInsight's assessment, globally, Interstitial Lung Disease pipeline constitutes 120+ key companies continuously working towards developing 120+ Interstitial Lung Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Interstitial Lung Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Interstitial Lung Disease Market.
The Interstitial Lung Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Interstitial Lung Disease Pipeline Report:
• Interstitial Lung Disease Companies across the globe are diligently working toward developing novel Interstitial Lung Disease treatment therapies with a considerable amount of success over the years.
• Interstitial Lung Disease companies working in the treatment market are AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, and others are developing therapies for the Interstitial Lung Disease treatment.
• Emerging Interstitial Lung Disease therapies such as AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280, Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation, Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others are expected to have a significant impact on the Interstitial Lung Disease market in the coming years.
• On March 2024, Boehringer Ingelheim announced a Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).
• On April 2024, Boehringer Ingelheim announced a Prospective, Observational Study on the Correlations Between Change in Lung Function and Change in Cough and Dyspnoea in Patients With Connective Tissue Disease-associated Progressive Fibrosing INTErstitial luNg diseaSE (CTD Associated PF-ILD) Treated With Nintedanib. The "INTENSE" Study.
• On January 2024, aTyr Pharma, Inc. announced a Randomized, Double-blind, Placebo-controlled Proof-of-Concept (PoC) Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD).

Interstitial Lung Disease Overview
Interstitial lung disease (ILD) encompasses a diverse group of disorders characterized by inflammation and scarring of lung tissue, leading to impaired gas exchange. Common symptoms include progressive dyspnea (shortness of breath), cough, and fatigue. ILD can be caused by various factors, including environmental exposures (such as asbestos or silica dust), autoimmune diseases (like rheumatoid arthritis or scleroderma), medications, and genetic predispositions. Diagnosis often involves a combination of clinical evaluation, imaging studies (such as high-resolution CT scans), pulmonary function tests, and sometimes lung biopsies. Treatment aims to alleviate symptoms, slow disease progression, and improve quality of life, and may include medications like corticosteroids, immunosuppressants, or antifibrotic agents. In some cases, lung transplantation may be considered for advanced disease. Prognosis varies depending on the specific type and severity of ILD, with some forms having a better outlook than others. Early detection and management are crucial in optimizing outcomes for patients with ILD.

Get a Free Sample PDF Report to know more about Interstitial Lung Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Interstitial Lung Disease Route of Administration
Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Interstitial Lung Disease Molecule Type
Interstitial Lung Disease Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Interstitial Lung Disease Pipeline Therapeutics Assessment
• Interstitial Lung Disease Assessment by Product Type
• Interstitial Lung Disease By Stage and Product Type
• Interstitial Lung Disease Assessment by Route of Administration
• Interstitial Lung Disease By Stage and Route of Administration
• Interstitial Lung Disease Assessment by Molecule Type
• Interstitial Lung Disease by Stage and Molecule Type

DelveInsight's Interstitial Lung Disease Report covers around 120+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Interstitial Lung Disease product details are provided in the report. Download the Interstitial Lung Disease pipeline report to learn more about the emerging Interstitial Lung Disease therapies- https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Interstitial Lung Disease Pipeline Analysis:
The Interstitial Lung Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Interstitial Lung Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interstitial Lung Disease Treatment.
• Interstitial Lung Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Interstitial Lung Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Interstitial Lung Disease market.

Download Sample PDF Report to know more about Interstitial Lung Disease drugs and therapies- https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of Interstitial Lung Disease Pipeline Drug Insight
• Coverage: Global
• Key Interstitial Lung Disease Companies: AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, and others.
• Key Interstitial Lung Disease Therapies: AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280, Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation, Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others.
• Interstitial Lung Disease Therapeutic Assessment: Interstitial Lung Disease current marketed and Interstitial Lung Disease emerging therapies
• Interstitial Lung Disease Market Dynamics: Interstitial Lung Disease market drivers and Interstitial Lung Disease market barriers

Request for Sample PDF Report for Interstitial Lung Disease Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Interstitial Lung Disease Report Introduction
2. Interstitial Lung Disease Executive Summary
3. Interstitial Lung Disease Overview
4. Interstitial Lung Disease- Analytical Perspective In-depth Commercial Assessment
5. Interstitial Lung Disease Pipeline Therapeutics
6. Interstitial Lung Disease Late Stage Products (Phase II/III)
7. Interstitial Lung Disease Mid Stage Products (Phase II)
8. Interstitial Lung Disease Early Stage Products (Phase I)
9. Interstitial Lung Disease Preclinical Stage Products
10. Interstitial Lung Disease Therapeutics Assessment
11. Interstitial Lung Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Interstitial Lung Disease Companies
14. Interstitial Lung Disease Key Products
15. Interstitial Lung Disease Unmet Needs
16 . Interstitial Lung Disease Market Drivers and Barriers
17. Interstitial Lung Disease Future Perspectives and Conclusion
18. Interstitial Lung Disease Analyst Views
19. Appendix
20. About DelveInsight

Request for Sample Report - https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Biochips Market: https://www.delveinsight.com/report-store/biochips-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Pain Management Devices Market: https://www.delveinsight.com/report-store/pain-management-devices-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-epidemiology-forecast
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Bartonellosis Market: https://www.delveinsight.com/report-store/bartonellosis-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Ocular Motility Disturbance Market: https://www.delveinsight.com/report-store/ocular-motility-disturbance-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Interstitial Lung Disease Clinical Trials Analysis 2024: FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight here

News-ID: 3538687 • Views:

More Releases from DelveInsight Business Research

Bipolar Disorder Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | AbbVie, Allergan, Novartis, Pfizer, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline Plc, J
Bipolar Disorder Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical T …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Bipolar Disorder pipeline constitutes 22+ key companies continuously working towards developing 22+ Bipolar Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Bipolar Disorder Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bipolar Disorder Market. The Bipolar
Cold Agglutinin Disease Market to Exhibit Rapid Growth Rate During the Forecast Period (2024-2034), Investigates DelveInsight | Apellis Pharma, Novartis, Incyte crp., Sanofi, Alexion Pharma
Cold Agglutinin Disease Market to Exhibit Rapid Growth Rate During the Forecast …
DelveInsight's "Cold Agglutinin Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cold Agglutinin Disease, historical and forecasted epidemiology as well as the Cold Agglutinin Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Cold Agglutinin Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cold Agglutinin Disease
Hereditary Angioedema Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | KalVista Pharma, Intellia Therapeutics, BioMarin Pharma, CSL Behring, Ionis Pharma
Hereditary Angioedema Market is Expected to Expand at a Healthy Growth Rate Duri …
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Hereditary Angioedema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hereditary Angioedema Market Forecast https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Benign Breast Disease and Early Breast Cancer Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Theraclion, IceCure Medical, U-Systems, Inc.
Benign Breast Disease and Early Breast Cancer Market Report 2032: Epidemiology D …
DelveInsight's "Benign Breast Disease and Early Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Benign Breast Disease and Early Breast Cancer, historical and forecasted epidemiology as well as the Benign Breast Disease and Early Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Benign Breast Disease and Early

All 5 Releases


More Releases for Lung

Lung Cancer Surgery Market
Allied Market Research (USA, Oregon, Portland) Published Latest Report titled, ‘Lung Cancer Surgery Market: Global Opportunity Analysis and Industry Forecast 2020-2027’. This market research study determines the increase in changes and the aspects which are likely to have an impact on the growth of the Lung Cancer Surgery Market. Increased demand for the technologies is also one of the factors, which are likely to boost the growth of this industry. The
Artificial Lung Market May Set New Growth Story | Breethe, Lung Biotechnology, M …
A new research document is added in HTF MI database of 37 pages, titled as 'Artificial Lung - Medical Devices Pipeline Assessment, 2020' with detailed analysis, Competitive landscape, forecast and strategies. The study covers important players/vendors such as ALung Technologies Inc, Breethe, Inc., Case Western Reserve University, Lung Biotechnology PBC, MC3 Inc, McGowan Institute for Regenerative , Medicine, Miromatrix Medical Inc, The Charles Stark Draper Laboratory Inc, U.S. Ann Arbor
11-11-2019 | Health & Medicine
CMI
Higher carcinoma lung population dominates the lung cancer therapeutics market
Lung cancer is a malignant lung tumor, which is characterized by uncontrolled division and growth of cells in the lungs. The ability of lungs to provide oxygen into the bloodstream decreases with increasing size of tumor. The lung carcinoma is classified as, non-small cell and small cell lung cancer and originates from the epithelial cells. Lung cancer has the highest mortality rate globally, where exposure to asbestos, cigarette and pipe
Lung Management Products Market Soaring Demand Assures Motivated Revenue Share d …
Lung management products are required for patients dealing with severe conditions such as asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and lung cancers. Lung management products are also used as a home-based care to exercise lungs and keep them healthy for a longer run. Several lung exercisers are available and being highly preferred. According to the American Lung Association, lung cancer was the most common cancer type in 2015
Artificial Lung Market Key Players 2018 - Haemair Ltd, Lung Biotechnology PBC, a …
Artificial Lung Overview: Medical Devices sector report, “Artificial Lung - Medical Devices Pipeline Assessment, 2018" provides an overview of Artificial Lung currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start
Lung Cancer Vaccine Market Lung Cancer Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents What are Cancer Vaccines? Mechanism of Cancer Vaccines 2.1 Idiotype Cancer Vaccine Mechanism 2.2 Cellular Cancer Vaccines Mechanism 2.3 Ganglioside Antigens based Cancer Vaccines Mechanism 2.4 Peptide Cancer Vaccine Mechanism 2.5 Tumor Host Interaction Cancer Vaccine Mechanism Overview of Lung Cancer Proliferation 3.1 Lung Cancer Invasion 3.1.1 Transformation of Normal Cell into